statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	686
SG - Singapore	209
CN - Cina	131
FI - Finlandia	87
IT - Italia	77
BR - Brasile	73
HK - Hong Kong	56
DE - Germania	47
VN - Vietnam	33
UA - Ucraina	27
GB - Regno Unito	25
PL - Polonia	22
FR - Francia	20
CA - Canada	18
TR - Turchia	17
RU - Federazione Russa	16
BD - Bangladesh	12
IN - India	11
NL - Olanda	11
IE - Irlanda	10
MX - Messico	8
JP - Giappone	7
ZA - Sudafrica	6
CZ - Repubblica Ceca	5
AR - Argentina	4
ES - Italia	3
PK - Pakistan	3
TW - Taiwan	3
AT - Austria	2
AZ - Azerbaigian	2
CR - Costa Rica	2
DZ - Algeria	2
GE - Georgia	2
ID - Indonesia	2
IQ - Iraq	2
IR - Iran	2
LT - Lituania	2
MA - Marocco	2
NO - Norvegia	2
PY - Paraguay	2
VE - Venezuela	2
AU - Australia	1
BE - Belgio	1
BO - Bolivia	1
CH - Svizzera	1
EC - Ecuador	1
EG - Egitto	1
ET - Etiopia	1
GM - Gambi	1
IL - Israele	1
JM - Giamaica	1
JO - Giordania	1
KZ - Kazakistan	1
LV - Lettonia	1
MN - Mongolia	1
MY - Malesia	1
NP - Nepal	1
PA - Panama	1
SA - Arabia Saudita	1
SE - Svezia	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
UZ - Uzbekistan	1
Totale	1.675

Nome	#
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	304
COVID-19 impact on consecutive neurological patients admitted to the emergency department	252
Where SUNCT Contacts TN: A Case Report	180
Un caso peculiare di ipertensione secondaria	121
Un caso peculiare di ipertensione arteriosa secondaria.	118
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study	98
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine	96
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine	86
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination	81
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor	75
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab	61
Photophobia and migraine outcome during treatment with galcanezumab	58
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination	57
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients	54
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation	54
Totale	1.695

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	29	0	0	0	0	0	0	0	0	0	13	9	7
2021/2022	54	2	19	0	0	0	2	4	2	4	4	6	11
2022/2023	62	5	4	1	3	5	11	0	12	13	2	2	4
2023/2024	75	4	1	10	5	1	19	0	1	12	1	13	8
2024/2025	402	8	0	4	62	27	29	32	30	48	39	70	53
2025/2026	817	76	90	45	113	89	87	169	42	58	48	0	0
Totale													1.695